Novartis To Pay $9.7bn For The Medicines Company
Bid Follows Strong Data For Twice-Yearly Gene Silencing Cholesterol Lowerer
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
